Journal

The Journal of Investment Management and New Frontier 2023 Harry M. Markowitz Award Winners

Retrieved on: 
Tuesday, March 26, 2024
Professional Services, Other Professional Services, Insurance, Finance, Asset Management, Banking, Hidden, Award, Investment management, Entrepreneurship, Federation, Knowledge, Journal, Research, Wind, Nobel Prize, AUM, Prasanta Chandra Mahalanobis, Hidden Markov model, Harry, Multimedia, Government, New Frontier, Film industry

The Journal of Investment Management ( JOIM ) and New Frontier announced today the winners of the 2023 Harry M. Markowitz Award.

Key Points: 
  • The Journal of Investment Management ( JOIM ) and New Frontier announced today the winners of the 2023 Harry M. Markowitz Award.
  • The award has been established to honor his legacy and to support future research and innovation in practical asset management.
  • “We are pleased to recognize the path-breaking work of the 2023 Award Winners who honor the impact of Harry Markowitz and his work in theoretical and applied modern portfolio theory,” said Robert Michaud, Co-Founder and Chief Investment Officer at New Frontier.
  • “Now in their fourteenth year, the Markowitz Awards reflect the highest-quality research being conducted in the market today.”

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Health, Mental Health, Depression, Conference, American Chemical Society, Patent, Acceleration, Partnership, HERG, Patient, CNS, Journal, Anxiety, IND, Chemical substance, Addiction, Safety, Therapy, Arthropathy, Medicinal chemistry, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.
  • “The fourth quarter of 2023 and early 2024 was a significant period for Enveric, highlighted by the selection of EB-003 as our lead development candidate.
  • Continued to strengthen our intellectual property portfolio, receiving ten patent issuances from the United States Patent and Trademark Office.
  • The gross proceeds to the Company from the two warrant exercises totaled approximately $4.5 million.

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

Retrieved on: 
Thursday, March 28, 2024
FDA, Health, Technology, Clinical Trials, Artificial Intelligence, Cardiology, Diagnosis, Coronary ischemia, Patient, Myocardial perfusion imaging, Journal, Ischemia, MD, American College, CCTA, Stenosis, Atherosclerosis, SPECT, Medical device

The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification.

Key Points: 
  • The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification.
  • For patients with an abnormal Cleerly AI-QCT ISCHEMIA finding, a positive result was associated with an approximately 7-fold increase of adverse cardiovascular events during an 8-year follow-up.
  • Collectively, this study shows that Cleerly AI-QCT ISCHEMIA, when used in conjunction with Cleerly LABS, can provide a 3-in-1 approach for the assessment of atherosclerosis, stenosis and ischemia.
  • These study results come after Cleerly announced that its Cleerly ISCHEMIA software device is billable using the new Category I CPT® code 75580.

Dr. Jean Giddens from Virginia Commonwealth University Appointed Chair of the AACN Board of Directors

Retrieved on: 
Monday, March 25, 2024
Nursing, Education, Health, Managed Care, Continuing, University, Training, RN, Learning, Nurse educator, Robin, Pacific Lutheran University, FAAN, Chairperson, Education minister, Colorado Mesa University, Virginia Association, Teaching, Eastern New Mexico University, Arizona State University, Journal, Research, Publication, Saint Francis University, Chair, Conference, Virginia Commonwealth University, School, AACN, Doctor of Philosophy, University of Alabama, Human

The American Association of Colleges of Nursing (AACN) is pleased to announce that Jean Giddens, PhD, RN, FAAN, ANEF, dean and professor of nursing at the Virginia Commonwealth University, has been appointed Chair of the AACN Board of Directors.

Key Points: 
  • The American Association of Colleges of Nursing (AACN) is pleased to announce that Jean Giddens, PhD, RN, FAAN, ANEF, dean and professor of nursing at the Virginia Commonwealth University, has been appointed Chair of the AACN Board of Directors.
  • Dr. Giddens officially began her two-year term as Board Chair at noon today following AACN’s Spring 2024 Business Meeting in Washington, DC.
  • Her distinguished career in nurse education encompasses leadership roles at the University of New Mexico, Mesa State College, University of Texas-El Paso, and Eastern New Mexico University.
  • In addition, AACN’s President and Chief Executive Officer Deborah Trautman serves as an ex-officio member of the AACN Board.

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

Retrieved on: 
Monday, March 25, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AbbVie, Ulcerative colitis, Growth, I&I, Cell, ACG, Patient, ABBV, UC, Journal, Biomarker, NIMML, Acquisition, LANCL2, IPO, SLE, Personalized medicine, Volunteering, A.I, IBD, Medicine, Rheumatoid arthritis, Epithelium, DRS, Invention, Therapy, NLRX1, Work, Pharmaceutical industry

and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.

Key Points: 
  • and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.
  • “Importantly, AbbVie is one of the world’s largest biopharma companies with an incredibly successful I&I franchise that it has built over the last two decades.
  • In addition to Landos Biopharma, Dr. Bassaganya-Riera founded NImmune Biopharma (“NImmune”) with the purpose to advance the clinical development of the LANCL2 portfolio of immunoregulatory precision medicines.
  • Both omilancor and NIM-1324 are guided by precision biomarkers discovered and developed by NIMML’s TITAN-X A.I.-powered Precision Medicine platform.

Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association

Retrieved on: 
Wednesday, March 20, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, JAMA, Lewy body, Diagnosis, Harvard Medical School, American Medical Association, DLB, MSA, Disease, PD, Multiple system atrophy, Alpha-synuclein, Physician, Journal, CND, MD, NIH, Synucleinopathy, Skin, Pathology, Bangladesh Technical Education Board, Medicare, PAF, Dementia, Phosphorylation, Medical imaging

The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.

Key Points: 
  • The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.
  • The proportion of patients with P-SYN was 92.7% in those with PD, 98.2% in those with MSA, 96.0% in those with DLB, and 100% in those with PAF.
  • Future disease-modifying therapies will require convenient, accurate, and precise diagnostic tools to reach the right patients at the right time across a wide array of communities.
  • “The publication of this important NIH-sponsored study is one big step forward with many more milestones to come.”

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Genetics, Research, Science, Biotechnology, ART, Radiation, SCC, Central Statistics Office (India), BWH, PNI, Risk, Patient, Journal, NCCN, Workflow, Dermatology, MPH, Recurrence, Metastasis, De-escalation, Medical imaging

Based on these gaps, the panel developed risk-based clinical recommendations and a workflow for ART referral in patients with SCC, which can be viewed in the JCAD article.

Key Points: 
  • Based on these gaps, the panel developed risk-based clinical recommendations and a workflow for ART referral in patients with SCC, which can be viewed in the JCAD article.
  • In nuanced discussions where the risks associated with ART may outweigh the benefits, the additional information provided by the DecisionDx-SCC test can assist in personalized decision-making.
  • The DecisionDx-SCC test can help radiation oncologists determine a more precise risk-benefit ratio for elective nodal radiation.
  • The panel recommended stronger consideration of elective nodal radiation for a DecisionDx-SCC Class 2B tumor, given the dramatically increased risk of nodal metastasis.

Alliance for Food and Farming: Studies, Government Data Discredit “Dirty Dozen” List

Retrieved on: 
Monday, March 18, 2024
FDA, Retail, Other Consumer, Organic Food, General Health, Women, Parenting, Men, Agriculture, Natural Resources, Supermarket, Family, Food, Beverage, Consumer, Health, Eating, Pesticide, USDA, Organization, Farmer, Vegetable, Risk, Journal, Research, Detergent, EWG, Poverty, PDP, DBA, Diet, Risk assessment, EPA, CDC, Pesticide Data Program, Water, Fruit, Safety, Toxicology, Work

The research also found that the list authors follow no scientifically established methodology in the development of their list.

Key Points: 
  • The research also found that the list authors follow no scientifically established methodology in the development of their list.
  • From Environmental Working Group’s (EWG) “Dirty Dozen” report: “The Shoppers Guide does not incorporate risk assessment into the calculations.
  • The Alliance for Food and Farming is a non-profit organization formed in 1989 which represents organic and conventional farmers.
  • Alliance contributors are limited to farmers of fruits and vegetables, companies that sell, market or ship fruits and vegetables or organizations that represent produce farmers.

New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment

Retrieved on: 
Monday, March 18, 2024
Mental Health, Managed Care, Medical Devices, Hospitals, Neurology, Science, Medical Supplies, Clinical Trials, Biotechnology, Health, Health Technology, Health Insurance, Other Science, Research, Radiology, Pharmaceutical, Seniors, Radiation, APS2, Certification, Brain, Alzheimer's disease, Deficit spending, Disease, Memory, AUC, Patient, Ageing, PET, Journal, Apolipoprotein, City, CLIA, Pathology, Medicare, Amyloid, Medical imaging

The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.

Key Points: 
  • The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.
  • The APS2 result was the most robust method among the individual plasma amyloid and tau analytes measured to identify disease.
  • In the published study, the PrecivityAD2 blood test was clinically validated in 583 individuals with cognitive impairment across two independent cohorts.
  • C₂N is working toward obtaining the requisite certification that will permit the PrecivityAD2 test to be available in New York in the near future.

Cosm Medical Achieves FDA Clearance for Gynethotics™ Pessaries, Pioneering the future of personalized pelvic care

Retrieved on: 
Thursday, March 14, 2024
Research, Medical Devices, Medical Supplies, FDA, Clinical Trials, Other Health, Biotechnology, Health, Science, Other Science, Pessary, Medicine, Partnership, Patient, Journal, Incontinence, University, Femtech, Health Canada, Trial of the century, Woman, Gynaecology, Prolapse, Birth control

Cosm Medical proudly announces FDA clearance for Gynethotics™ Pessaries, marking it as the first personalized pessary available to patients.

Key Points: 
  • Cosm Medical proudly announces FDA clearance for Gynethotics™ Pessaries, marking it as the first personalized pessary available to patients.
  • This milestone follows a recent Health Canada clearance and marks a significant advancement in pelvic care, emphasizing Cosm’s commitment to enhancing patient outcomes and revolutionizing treatment options for women worldwide.
  • Gynethotics™ are the first pessary to be FDA cleared in about 5 years with almost 10 million pessary configurations that clinicians can conveniently order online.
  • “Our vision is to become the world leader in precision gynecological devices for unique bodies and needs.” said Derek Sham, Founder & CEO of Cosm Medical.